Infectious disease
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
Newly announced results of a Phase I dose-escalation study show CureVac’s COVID-19 vaccine candidate, CVnCoV, generates noticeable immune responses in healthy volunteers.
During a Sunday campaign event in Florida, President Donald Trump appeared to hint to the crowd that following the Nov. 3 election, he would terminate the decades-long tenure of Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.
BioSpace caught up with Icosavax CEO Adam Simpson to discuss its new vaccine candidate, IVX-411.
There is an impressive amount of technological ingenuity – mRNA, monoclonal antibodies and more traditional formats – being thrown at the development of a vaccine against COVID-19.
The sound of coughing and gasping breath is coming up fast. A slow look over your shoulder reveals the sweaty, nightmare visage of COVID-19 – or does it?
The U.S. – and global – response to the COVID-19 pandemic has been volatile at best. This is fair, considering that SARS-CoV-2 is a novel virus with a lethality we haven’t seen in more than a century.
The decision to halt critically ill patients was made in response to Regeneron’s independent safety board finding a potential safety signal and an unfavorable risk-benefit profile of the monoclonal antibody therapy in a subgroup of patients requiring high-flow oxygen or mechanical ventilation.
A seroprevalance study of 15,591 children in Bavaria, published October 28th in Med, revealed a six-fold greater prevalence of the SARS-CoV-2 virus than reported cases.
Novo Nordisk announced today that it has ended its development of the anti-IL-21 antibody NN9828 in combination with Victoza. The decision was made after analyzing Phase II clinical trial data in patients with Type 1 diabetes.
PRESS RELEASES